Table 1.
Viability of leukemia and normal specimens in response to parthenolide
|
5 μM parthenolide
|
7.5 μM parthenolide
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
CD34+
|
Total
|
CD34+
|
Total
|
|||||||
| Specimens | FAB subtype | Cytogenetics | Average % viable* | SD | Average % viable* | SD | Average % viable* | SD | Average % viable* | SD |
| AML specimens | ||||||||||
| AML1 | M2 | Probable 11q23 | 3.5 | 1.6 | 26.2 | 10.2 | 4.6 | 1.3 | 34.0 | 8.2 |
| AML2 | M4 | Trisomy 8 and 13 | 6.0 | 3.3 | 18.2 | 3.4 | 10.6 | 6.4 | 22.2 | 9.6 |
| AML3 | M4 (AML2 relapse) | Trisomy 8 and 13 | 24.2 | 3.9 | 44.9 | 3.6 | 18.2 | 2.0 | 32.5 | 4.2 |
| AML4 | M4 | Normal | 4.9 | 1.0 | 30.9 | 1.6 | 4.3 | 0.3 | 24.9 | 1.5 |
| AML5 | M4 (AML4 relapse) | Normal | 1.5 | 0.2 | 7.2 | 1.7 | 2.6 | 2.6 | 6.6 | 3.3 |
| AML6 | MDS | Monosomy 7, 11q23 abnormalities | 10.5 | 1.5 | 18.7 | 2.3 | 8.5 | 2.2 | 14.7 | 1.9 |
| AML7 | M1 | Normal | 5.3 | 1.8 | 9.9 | 2.0 | 3.1 | 0.2 | 1.6 | 1.0 |
| AML8 | M2 | Normal | 7.5 | 0.8 | 13.2 | 2.8 | 5.1 | 2.0 | 8.9 | 1.4 |
| AML9 | MDS | 16q22 (cbFBx2) | 7.1 | 2.0 | 29.7 | 4.8 | 1.2 | 0.3 | 8.2 | 0.6 |
| AML10 | M5 | ND | 68.1 | 12.2 | 90.7 | 11.1 | 7.3 | 1.2 | 31.7 | 2.5 |
| AML11 | M2/M4 | t(8;21) | 3.7 | 1.4 | 24.6 | 2.4 | 1.7 | 0.7 | 14.3 | 5.8 |
| AML12 | M5 | Normal | 18.5 | 1.9 | 37.5 | 2.7 | 4.8 | 1.2 | 3.3 | 1.5 |
| AML13 | M4 | Deletion of chromosome 7 | 57.3 | 6.1 | 53.9 | 6.3 | 6.8 | 1.0 | 11.2 | 2.5 |
| AML14 | M4 | ND | 16.9 | 3.2 | 25.7 | 3.3 | 17.7 | 2.0 | 25.0 | 1.7 |
| Geometric mean | NA | NA | 9.3† | 24.9 | 4.9‡ | 13.8 | ||||
| 95% CI | NA | NA | 5.3, 16.2 | 17.6, 35.1 | 3.3, 7.5 | 9.5, 20.1 | ||||
| CML specimens | ||||||||||
| CML1 | bcCML | t(9:22) | 37.0 | 0.9 | 39.3 | 1.1 | 8.1 | 0.5 | 22.0 | 1.6 |
| CML2 | bcCML | t(9:22) | 16.8 | 2.2 | 30.8 | 5.2 | 16.9 | 2.2 | 30.7 | 7.1 |
| CML3 | bcCML | t(9:22) | 61.4 | 0.8 | 47.0 | 1.3 | 19.7 | 9.4 | 24.2 | 6.8 |
| CML4 | bcCML | t(9:22) | 5.1 | 2.9 | 15.6 | 7.5 | 5.3 | 1.0 | 14.2 | 3.5 |
| Geometric mean | NA | NA | 20.2§ | 29.9 | 10.7|| | 21.6 | ||||
| 95% CI | NA | NA | 7.5, 54.4 | 19.1, 47.0 | 6.4, 18.0 | 16.4, 28.5 | ||||
| Normal specimens | ||||||||||
| N1 | NA | NA | 98.4 | 1.5 | 93.5 | 8.1 | 98.8 | 1.7 | 97.5 | 3.0 |
| N2 | NA | NA | 85.3 | 5.5 | 100.0 | 0.1 | 55.0 | 11.9 | 100.0 | 0.3 |
| N3 | NA | NA | 93.9 | 18.6 | 98.5 | 5.2 | 71.1 | 27.1 | 97.0 | 8.9 |
| N4 | NA | NA | 70.6 | 7.9 | 84.6 | 5.0 | 57.0 | 16.8 | 75.0 | 6.1 |
| N5 | NA | NA | 92.2 | 1.8 | 96.4 | 2.1 | 73.5 | 1.7 | 95.6 | 2.3 |
| N6 | NA | NA | 99.7 | 1.1 | 100.0 | 2.2 | 96.8 | 1.2 | 100.6 | 2.0 |
| N7 | NA | NA | 98.8 | 1.1 | 97.9 | 3.8 | 96.8 | 1.6 | 98.9 | 2.1 |
| Geometric mean | NA | NA | 93.4 | 92.8 | 86.5 | 82.1 | ||||
| 95% CI | NA | NA | 85.4, 102.2 | 88.5, 97.2 | 74.0, 101.2 | 69.4, 97.1 | ||||
ND indicates not determined; and NA, not applicable.
*
Viability normalized to untreated controls
†
10.1-fold lower viability (P < .001) than healthy subjects
‡
17.5-fold lower viability (P < .001) than healthy subjects
§
4.6-fold lower viability (P = .003) than healthy subjects
||
8.1-fold lower viability (P < .001) than healthy subjects